

Targeted Toxins from Here to There

(continued from page 1)

Ron Wiley and I, the discoverers of the widely used SP-SAP, cover the use of that molecule and the mu opioid receptor-targeted toxin, dermorphin-SAP. This article, and the following one by the group of Peter Shiromani involving the use of orexin-SAP, should leave the reader well-grounded in the use of the peptide-ligand toxins.

The final two chapters of the book discuss the use of the lectin toxins IB4-SAP and CTB-SAP. These articles show the promise of lectins to be carriers of saporin. Others such as wheat germ are in a vein that hasn't been sufficiently mined yet.

This book shows the promise of targeted toxins that will be fulfilled as more targeting agents become available.



Order \$500 or more of ATS products during the month of July and receive a free copy of *Molecular Neurosurgery With Targeted Toxins*.

(one book per customer, please)

Society for Neuroscience
November 12-16, 2005
Washington DC



Upcoming Events

Cell Biology
December 10-14, 2005
San Francisco, CA

SP-SAP Partnering Opportunity

Advanced Targeting Systems has received over \$3 million in funding from the National Institutes of Health, National Institute of Mental Health for the development of SP-SAP (Substance P-Saporin) as a chronic pain therapeutic. In addition to the cash contribution, the NIH recently established a Commercialization Assistance Program to further enable grantees to bring their products to market.

Denise Higgins, Vice President of Business Development, participated in the program that culminated with the production of a Business Plan and presentation of the Partnering Opportunity at the 11th Annual Venture Forum. This meeting, organized each year by the Larta Institute, showcased seventy of the participating life science companies.

Although the audience was primarily comprised of investors, there were good contacts made with several pharmaceutical companies that are excellent candidates to bring SP-SAP to market to the chronic pain population.

ATS is hopeful that there will be a formal announcement of a partnership in time for the fourth quarter issue of *Targeting Trends*. The sooner a deal can be finalized, the sooner clinical trials can begin and SP-SAP can offer relief to those suffering from chronic pain.



More New Antibodies

Advanced Targeting Systems continues to offer new antibodies. Take a look at our website for a list of more than 350 antibodies for neuroscience, GPCRs, and more.

Cat.#	Antibody Name	Specificity
AB-L005	Adenosine A1 Receptor	Human; Mouse; Rat
AB-L006	Adenosine A2a Receptor	Human; Mouse; Rat
AB-L007	Adenosine A3 Receptor	Human; Mouse; Rat
AB-L356	Brain-Specific Angiogenesis Inhibitor 1	Human
AB-L198	Brain-Specific Angiogenesis Inhibitor 2	Human
AB-L199	Brain-Specific Angiogenesis Inhibitor 3	Human; Mouse
AB-L084	Histamine H1 Receptor	Human; Mouse; Rat
AB-L345	Histamine H2 Receptor	Human; Mouse; Rat
AB-L085	Histamine H3 Receptor	Human; Mouse; Rat
AB-L086	Histamine H4 Receptor	Human; Mouse; Rat
AB-L351	Orexin Receptor 1	Rat
AB-L248	Prokineticin Receptor 1 (GPR73A)	Human; Mouse; Rat
AB-L249	Prokineticin Receptor 2 (GPR73B)	Human; Mouse; Rat
AB-L259	Thrombin Receptor	Human; Mouse; Rat